Ken Griffin Harvard Bioscience Inc Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 42,400 shares of HBIO stock, worth $27,560. This represents 0.0% of its overall portfolio holdings.

Number of Shares

42,400

Previous 79,800 46.87%

Holding current value

$27,560

Previous $35,000 48.57%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.57 - $2.19 $148,911 - $572,133	261,248 Added 380.19%	329,964 $188,000
Q4 2024 Feb 14, 2025	SELL	$2.02 - $2.82 $95,501 - $133,323	-47,278 Reduced 40.76%	68,716 $144,000
Q3 2024 Nov 14, 2024	SELL	$2.64 - $3.54 $24,750 - $33,187	-9,375 Reduced 7.48%	115,994 $312,000
Q2 2024 Aug 14, 2024	BUY	$2.77 - $4.63 $294,680 - $492,553	106,383 Added 560.32%	125,369 $357,000
Q1 2024 May 15, 2024	BUY	$4.02 - $5.39 $76,323 - $102,334	18,986 New	18,986 $80,000

Q3 2023 Nov 14, 2023	SELL	$4.0 - $5.82 $7,504 - $10,918	-1,876 Reduced 49.81%	1,890 $8,000
Q2 2023 Aug 14, 2023	SELL	$4.19 - $6.16 $112,547 - $165,463	-26,861 Reduced 87.7%	3,766 $20,000
Q1 2023 May 15, 2023	SELL	$2.45 - $4.22 $28,045 - $48,306	-11,447 Reduced 27.21%	30,627 $128,000
Q4 2022 Feb 14, 2023	BUY	$2.12 - $2.86 $56,898 - $76,759	26,839 Added 176.17%	42,074 $116,000
Q3 2022 Nov 14, 2022	SELL	$2.33 - $3.92 $311,539 - $524,135	-133,708 Reduced 89.77%	15,235 $39,000
Q2 2022 Aug 15, 2022	BUY	$3.28 - $6.42 $422,591 - $827,146	128,839 Added 640.86%	148,943 $537,000
Q1 2022 May 16, 2022	BUY	$5.16 - $7.14 $38,488 - $53,257	7,459 Added 58.99%	20,104 $125,000
Q3 2021 Nov 15, 2021	SELL	$6.98 - $8.47 $2,708 - $3,286	-388 Reduced 2.98%	12,645 $88,000
Q1 2021 May 17, 2021	BUY	$3.91 - $6.99 $50,959 - $91,100	13,033 New	13,033 $71,000
Q3 2020 Nov 16, 2020	SELL	$2.75 - $4.2 $123,431 - $188,512	-44,884 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$2.12 - $3.14 $29,226 - $43,288	-13,786 Reduced 23.5%	44,884 $139,000
Q2 2019 Aug 14, 2019	SELL	$1.93 - $4.59 $2,244 - $5,338	-1,163 Reduced 1.94%	58,670 $118,000
Q3 2018 Nov 13, 2018	BUY	$5.0 - $6.65 $235,120 - $312,709	47,024 Added 367.12%	59,833 $0
Q1 2018 May 11, 2018	BUY	$3.3 - $5.15 $42,269 - $65,966	12,809 New	12,809 $64,000

Others Institutions Holding HBIO

# of Institutions

Shares Held

19.5M

Call Options Held

54K

Put Options Held

View Full List

About HARVARD BIOSCIENCE INC

Ticker HBIO
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 41,636,500
Market Cap $27.1M
Description
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...

More about HBIO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account